Am J Med

1. ITO H
   An Inevitable Challenge in Primary Prevention of Upper Gastrointestinal Bleeding Among Aspirin Users: Appropriate Use of Proton Pump Inhibitors.
   Am J Med. 2024;137:e98.
   

   >> Share

   
   

   
   Dig Dis Sci

2. DING YM, Duan M, Han ZX, Song XH, et al
   Bismuth-Containing Quadruple Therapy for Helicobacter pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days.
   Dig Dis Sci. 2024 May 3. doi: 10.1007/s10620-024-08460.
   

   >> Share

   
   

   
   Gastrointest Endosc

3. NOH CK, Lee GH, Lee E, Park B, et al
   Comparative diagnostic performance of rapid urease test with the sweeping method versus tissue sampling method after Helicobacter pylori eradication.
   Gastrointest Endosc. 2024 Apr 29:S0016-5107(24)03160.
   

   >> Share

   
   

   
   Gut

4. YUAN S, Larsson SC, Gill D, Burgess S, et al
   Concerns about instrumental variable selection for biological effect versus uptake of proton pump inhibitors in Mendelian randomisation analysis.
   Gut. 2024 May 2:gutjnl-2024-332280. doi: 10.1136/gutjnl-2024-332280.
   

   >> Share

   
   
5. DUTTA AK, Sharma V, Jain A, Elhence A, et al
   Inappropriate use of proton pump inhibitors in clinical practice globally: a systematic review and meta-analysis.
   Gut. 2024 Apr 26:gutjnl-2024-332154. doi: 10.1136/gutjnl-2024-332154.
   

   >> Share

   
   

   
   Helicobacter

6. GUAN X, Ning J, Fu W, Wang Y, et al
   Helicobacter pylori with trx1 high expression promotes gastric diseases via upregulating the IL23A/NF-kappaB/IL8 pathway.
   Helicobacter. 2024;29:e13072.
   

   >> Share

   
   
7. CHEN J, Zhang Y, Min H, Zhi J, et al
   Dynamic changes in the gut microbiota after bismuth quadruple therapy and high-dose dual therapy for Helicobacter pylori eradication.
   Helicobacter. 2024;29:e13077.
   

   >> Share

   
   
8. AMIOT A, Hacoon J, Heluwaert F, Mion F, et al
   14-day tailored PCR-guided triple therapy versus 14-day non-Bismuth concomitant quadruple therapy for Helicobacter pylori eradication: A multicenter, open-label randomized noninferiority controlled trial.
   Helicobacter. 2024;29:e13076.
   

   >> Share

   
   
9. STERBENC A, Godnov U, Vodicar PM, Simcic S, et al
   Prevalence of Helicobacter pylori infection among Slovenian children and adolescents: A prospective cohort study.
   Helicobacter. 2024;29:e13082.
   

   >> Share

   
   
10. KATO M, Ono S, Kawada K, Dohi O, et al
    Diagnostic performance of linked color imaging for gastric cancer by Helicobacter pylori infection status: A subanalysis of the large-scale, multicenter randomized controlled trial LCI-FIND.
    Helicobacter. 2024;29:e13080.
    

    >> Share

    
    
11. AGAWA H, Tsukadaira T, Kobayashi N, Kodaira H, et al
    Four cases of non-Helicobacter pylori Helicobacter-infected gastritis with duodenal spiral bacilli.
    Helicobacter. 2024;29:e13083.
    

    >> Share

    
    

    
    J Ethnopharmacol

12. SANCHEZ-QUEZADA V, Velazquez-Guadarrama N, Mendoza-Elizalde S, Hernandez-Iturriaga M, et al
    Bioaccessibility of bioactive compounds present in Persea americana Mill. seed ingredient during oral-gastric digestion with antibacterial capacity against Helicobacter pylori.
    J Ethnopharmacol. 2024 Apr 27:118259. doi: 10.1016/j.jep.2024.118259.
    

    >> Share

    
    

    
    J Gastroenterol Hepatol

13. ZHAO X, Ciren Y, Wu D
    Gastrointestinal: A rare intra-abdominal hydatid cyst manifesting as an acute massive upper gastrointestinal bleeding.
    J Gastroenterol Hepatol. 2024 May 2. doi: 10.1111/jgh.16579.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share